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Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African
meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A
(MenA). It is important to consider how best to sustain population protection in the long term.
Methods. We created a mathematical model of MenA transmission and disease to investigate the potential im-
pact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and
immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic
forcing term that models between year variation in rates of transmission. Model parameters were primarily derived
from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with
irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses.
Results. Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease
control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approxi-
mately 15 years (assuming 10 years’ average vaccine protection). Routine immunization at 9 months of age resulted
in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above
approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was
achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months,
5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds.
Conclusions. These results can be used to inform policy recommendations for long-term vaccination strategies
with MenAfriVac.
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The African meningitis belt suffers from frequent large
epidemics of meningococcal meningitis. A novel vac-
cine against Neisseria meningitidis group A (MenA),
the major cause of epidemic meningitis, was developed
through the Meningitis Vaccine Project (MVP), man-
ufactured by the Serum Institute of India, Ltd [1]. The
vaccine, known as MenAfriVac, was ﬁrst introduced
into Burkina Faso, Mali, and Niger in 2010 in mass
immunization campaigns targeting 1- to 29-year-olds.
MenAfriVac continues to be rolled out across the region,
and >217 million individuals have been immunized to
date. These campaigns have been remarkably successful
in the short term in reducing the incidence of meningitis
and the prevalence of MenA carriage, as shown in
Burkina Faso [2, 3] and Chad [4]. To ensure that this
success continues, long-term immunization strategies
are required to maintain population protection.
Computational models have become an important
tool for vaccine policy makers. By simulating the im-
pact of a vaccine in silico, a wide range of vaccine strat-
egies can be explored and the sensitivity of their
predicted impact to structural and parameter uncer-
tainty can be understood. Transmission dynamic
models are essential to quantify both the direct and
indirect (herd protection) effects of vaccination pro-
grams. For meningococcal infection, most transmis-
sion occurs between asymptomatic carriers, so any
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model attempting to capture the transmission dynamics of
meningococci must essentially include the carrier state. This
is especially relevant when considering the impact of MenAfri-
Vac, given the evidence that MenA carriage is much reduced
following MenAfriVac introduction [2, 4]. This is likely to give
rise to large indirect vaccine effects, as seen with other con-
jugate vaccines [5]. Other key features of the epidemiology of
MenA in the African meningitis belt must also be incorporat-
ed, which include the periodic but irregular nature of epidem-
ics of varying size; the seasonality of meningitis with epidemics
occurring in the dry season and dying out with the onset of the
rains [6]; and the variation in disease risk [7] and carriage prev-
alence [8] by age.
A range of transmission models for meningococcal infection
has been developed [9–11]. Only 2 have speciﬁcally examined
MenA in the African meningitis belt. Irving et al [12] explored
the potential mechanisms underlying the striking epidemiology
in this region, showing that the complex and irregular timing of
epidemics could be explained by the interaction of temporary
immunity conferred by carriage of the bacteria together with
seasonal changes in the transmissibility of infection. Tartof
et al [13] used a transmission model to investigate different
strategies using MenAfriVac.
Here we extend the transmission models of Irving et al [12]
by addressing some of the limitations (such as the lack of age
structure and wide parameter space considered), and incor-
porating vaccination. We utilize recently available MenA/
MenAfriVac speciﬁc parameters and apply the model to in-
vestigate appropriate policy options for the sustained use of
MenAfriVac.
METHODS
Model Structure
We developed a compartmental model that divides the popula-
tion into the following states: (1) susceptible, (2) carrier of
MenA, (3) disease due to MenA, and (4) recovered and im-
mune, based on our previous investigations of simple determin-
istic models [12], and in vaccinated populations a mirror of
these 4 states (Figure 1). The population is further structured
by age into 19 age groups: 0 to <3 months, 3 to <9 months, 9
to <12 months, 1–4 years, 5–9 years, and 5-year age groups to
age 80 years subsequently, with continuous aging between
groups (rates of aging from one age group to another are
given in Supplementary Table 1). The proportion of the popu-
lation that is in each age group does not change over time.
Vaccination was implemented in different ways according to
the strategy used (Table 1). For mass vaccination campaigns, we
assumed that immunization occurred as a discrete event at one
point in time, whereas routine immunization was implemented
continuously as individuals reached the target age for the Ex-
panded Programme on Immunization (EPI). The narrow age
groups in <1-year-olds allowed routine vaccination to be imple-
mented at different ages.
An important feature of the meningitis belt is the prominent
seasonality [6] of disease, which we implemented through sea-
sonal forcing of the transmission and invasion rates using a si-
nusoidal function [12]. The baseline transmission rate was
varied stochastically drawing from a uniform distribution be-
tween 0.8 and 1.2 (ie, ±20%) each year to reﬂect between-year
variation in transmission due to climatic [14] or other external
Figure 1. Diagram of the model for Neisseria meningitidis group A transmission and disease. Each compartment is divided into distinct age classes (not
shown). See Table 1 for deﬁnition of parameters and Supplementary Material for the full model structure.
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variability. To examine the sensitivity of results to this model
structure, we introduced stochasticity in an alternative way,
with weekly variation in transmission rates, drawn from the
same uniform distribution (0.8–1.2). This “noisy” model used
a method similar to the stochastic mechanism used by Tartof
et al [13], but with the stochastic term drawn from a narrower
range.
Full details of the model structure are given in the Supple-
mentary Material, section A.
Model Parameters
Model parameters (Table 2) were based on the available litera-
ture, and African data wherever possible. Demographic para-
meters were based on Burkina Faso, a country at the heart of
the meningitis belt. Different “who acquires infection from
whom” (WAIFW) matrices were used and compared. In the ab-
sence of empirical data on population contact patterns, we used
evidence on the age distribution of carriers during an MenA ep-
idemic to inform these matrices [20]. The WAIFW matrix used
is shown in Supplementary Figure 1; contacts are more intense
between individuals in the same age group and particularly so
for older children and young adults. It was necessary to estimate
values for some parameters where direct evidence was lacking.
In exploring the parameter space, it was apparent that there was
a strong co-linear relationship between the transmission rate
and duration of colonization. Direct estimation of model pa-
rameters is complicated by the intractability of the likelihood
function for this model and the limitations of available inci-
dence data. As a ﬁrst exploration of model behavior to guide
Table 1. Vaccination Strategies Considered
Vaccine Strategy Introduction Long-term
A. Initial
campaign only
Mass immunization
of 1- to 29-year-olds
Nothing
B. Periodic
campaigns
Mass immunization
of 1- to 29-year-olds
Periodic mass
immunization of 1- to
4-year-olds
C. Routine EPI
single dose
Mass immunization
of 1- to 29-year-olds
Routine EPI at 9 mo, 5 y
after introduction
D. Combination Mass immunization
of 1- to 29-year-olds
Routine EPI at 9 mo, 5 y
after introduction,
plus catch-up for 1- to
4-year-olds
Abbreviation: EPI, Expanded Programme on Immunization.
Table 2. Model Parameters
Parameter
Parameter
Name Value Unit Comment [Reference]
Mortality rate d Age-specific Years−1 Census reports (Supplementary Table 2)
Recovery rate from disease ρ 52 Years−1 Disease lasts about a week [15]
Rate of loss of carriage α 12 Years−1 Only 1 study identified, suggesting 1-mo duration of
MenA [16]
Transmission rate β0 10.5 . . . Estimate
Rate at which carriers fall ill a Age-specific Years−1 Systematic review of case: carrier ratios [17], age-
specific parameters estimated (Supplementary
Table 3)
Rate of loss of immunity ϕ 0.0839 Years−1 Estimate, based on previous findings [12]
Seasonal forcing of transmission rate ɛβ 0.6 . . . Estimate, based on previous findings [12]
Seasonal forcing of invasion rate ɛa 0.6 . . . Seasonality in invasion rate based on published
systematic review [17]
Annual growth rate q 0.0309 Years−1 Census reports
Rate of progression between age groups K Age-specific Years−1 Estimated using mortality rates and annual population
growth rate (Supplementary Table 2)
Vaccine efficacy against carriage δ 0.6–0.9 Proportion Range explored, 0.9 from [4]
Vaccine efficacy against disease ξ 0.6–0.9 Proportion Range explored, 0.9 from [4]
Carriage clearage upon vaccination σ 0.9 Proportion Unknown, effect explored in sensitivity analysis
Waning of vaccine protection w 0.1 Years−1 Consistent with findings from unpublished MVP trials.
Varied in sensitivity analysis
Vaccination coverage for initial mass
campaign
vA 0.95 Proportion Coverage surveys [18, 19]
Vaccination coverage for additional mass
campaigns
vB 0.6–0.8 Proportion Unknown, range explored. 80% used in base case
Vaccination coverage for EPI vC 0.5–0.8 Proportion Range taken from typical EPI coverage in meningitis
belt countries. 80% used in base case
Abbreviations: EPI, Expanded Programme on Immunization; MenA, Neisseria meningitidis group A; MVP, Meningitis Vaccine Project.
S596 • CID 2015:61 (Suppl 5) • Karachaliou et al
 at U
niversity of Cam
bridge on N
ovem
ber 18, 2015
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
inference, we found a number of different plausible combina-
tions of parameter values for the transmission rate and duration
of natural immunity, which were able to produce realistic results
when used in our model and deﬁned a possible range for the
unknown parameters.
Model Implementation
The model was coded and run using the R package version
3.1.0, using the package deSolve to perform the numerical inte-
gration of differential equations. The time step was 1 day. For
each simulation, we ran the model for a 20-year burn-in period
before implementing the initial mass vaccination campaign in
year 0. The model was then run for a further 40 years; all results
are reported for this 40-year period. For each vaccination strat-
egy, the average of 300 simulations was taken; this was based on
a comparison of between 100 and 500 simulations that showed
very small marginal differences between 300 and 500 simulations.
Vaccination Strategies
We considered a range of long-term vaccination strategies and
compared these to a scenario without any vaccination and with
only an initial mass vaccination campaign of 1- to 29-year-olds
(Table 1). We also investigated the sensitivity of the results to
changes in the age at EPI immunization and the coverage
achieved for EPI immunization at 9 months.
RESULTS
Base Case
In the absence of preventive vaccination, the model was able to
capture the distinctive epidemiology of meningococcal infection
in the meningitis belt. A typical model run, with irregular epi-
demics of varying size, is shown in Figure 2.
Following initial mass vaccination of 1- to 29-year-olds, the
model predicted a resurgence in disease after approximately 15
years, assuming an average of 10 years of vaccine protection
(Figure 3).
Of the long-term immunization strategies considered, all
were effective in maintaining control of disease. There was con-
siderable overlap in the distribution of results (Figure 4), but
routine EPI immunization at 9 months of age (strategy C) re-
sulted in lower average annual incidence than regular mass
campaigns of 1- to 4-year-olds (strategy B) under base case as-
sumptions. Strategy C was superior to strategy B provided that
EPI coverage was above approximately 60% (Table 3). The strat-
egy with the lowest overall average annual incidence and longest
time to resurgence was introduction into EPI at 9 months, 5
years after the initial mass campaigns, with a catch-up targeting
unvaccinated children aged 1–4 years (strategy D).
Sensitivity Analyses
We investigated the effect of changing some key model param-
eters and assumptions. In the absence of any long-term immu-
nization (strategy A), assuming a shorter duration of protection
resulted in disease incidence increasing more quickly; with 5
years of vaccine protection, the resurgence occurred after
around 10 years (not shown).
For strategy C (routine EPI), as expected, as EPI coverage in-
creased, the incidence of disease decreased (Table 3). For every
10% increase, the average annual incidence decreases by
Figure 2. A typical run of the Neisseria meningitidis group A transmis-
sion model.
Figure 3. Results from 300 simulations of the initial mass immunization
of 1- to 29-year-olds (implemented in year 0). The black dashed line depicts
the mean annual incidence.
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approximately 1 case per 100 000 population per year. Also
consistent with expectations, disease control was better when
vaccine effectiveness was higher (not shown).
We observed only marginal differences by varying the age
at which routine MenAfriVac was given. The average disease
incidence across all ages decreased as the age at immunization in-
creased from 3 to 9 to 12 months of age. However, there were more
cases in infants as the age at routine immunization increased.
When averaged across 300 simulations, when MenAfriVac
was given routinely at the age of 3 months, the model predicts
an average annual incidence of 5.43 cases per 100 000 popula-
tion per year in all ages and 4.67 cases per 100 000 individuals in
infants, compared with the base case of immunization at 9
months (average incidence of 5.31 cases/100 000 across all
ages and 8.77 cases/100 000 infants). Immunizing within EPI
at 12 months of age results in an average annual incidence of
5.18 cases per 100 000 population, but 10.53 cases per 100 000
in infants.
The model results were insensitive to changes in the assump-
tion of vaccine effectiveness against disease (ξ) when vaccine ef-
fectiveness against carriage (δ) was high (90%), because in this
situation, carriage acquisitions were rare and so few people were
at risk of disease downstream. Because it is unclear whether the
vaccine can clear an episode of carriage, we also investigated the
sensitivity of the results to changes in clearance upon vaccination.
In the base case, we assumed that 90% of the carriers recover im-
mediately after vaccination; when this proportion was changed to
10%, we found that the results were insensitive to the change.
The duration of natural immunity following carriage or dis-
ease is not known. In the base case, we assumed on average ap-
proximately 12 years’ duration of immunity. When this was
lowered to 7 years, keeping other parameters ﬁxed, the inci-
dence of disease under all scenarios was higher. However, the
relative ranking of each strategy did not change.
The sensitivity of our results to changes in the model struc-
ture were also investigated. The results from the “noisy” model
in which the transmission rate varied stochastically each week
were very similar to the results presented above.
Figure 4. Box plot to show the median, interquartile range, and full
range of the predicted annual incidence per 100 000 for different immuni-
zation strategies in the 40 years following vaccine introduction from 300
model simulations.
Table 3. Estimated Average Annual Neisseria meningitidis Group A Incidence per 100 000 in the 40 Years Following Vaccine Introduction
Under Different Immunization Strategies and Coverage Assumptions
Age, y
No
Vaccination
Strategy A
Strategy B
Strategy C Strategy D
Mass
1–29 y
Only
Mass 1–29 y
and EPI at 9 mo
at 50%
Coverage
Mass 1–29 y
and EPI at 9 mo
at 60%
Coverage
Mass 1–29 y
and EPI at 9 mo
at 70%
Coverage
Mass 1–29 y
and EPI at 9 mo
at 80%
Coverage
Mass 1–29 y
and Periodic
Mass Campaigns
of 1–4 y
Mass 1–29 y
Plus EPI at 9 mo
and 1–4 y
Catch-up
<1 40.32 27.71 14.87 12.49 10.52 8.77 13.52 7.50
1–4 37.38 25.82 10.12 7.94 6.04 4.43 7.15 3.80
5–9 42.54 28.76 13.26 10.92 8.82 6.92 10.00 5.91
10–14 38.61 26.82 14.66 12.57 10.59 8.71 11.48 7.43
15–19 32.14 23.05 14.86 13.24 11.60 9.96 12.10 8.51
20–24 19.18 14.06 9.89 8.99 8.03 7.05 8.26 6.07
25–29 11.20 8.36 6.02 5.51 4.94 4.36 5.10 3.80
≥30 3.18 2.35 1.55 1.39 1.23 1.07 1.30 0.94
All 24.45 17.06 9.01 7.69 6.46 5.31 7.12 4.56
Unless otherwise stated, the coverage attained in the initial mass campaign among 1- to 29-year-olds was 95%, and routine and subsequent catch-up coveragewas
80%.
Abbreviation: EPI, Expanded Programme on Immunization.
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DISCUSSION
We developed a model of MenA transmission and disease that
was able to describe the epidemiology observed in the African
meningitis belt. We simulated the impact of the initial mass
vaccination campaigns of 1- to 29-year-olds and predicted a
period of very low incidence for at least 10 years, even when
assuming a relatively short duration of protection. The indirect
effects of the vaccine were clearly important in maintaining
this low incidence postintroduction; we assumed a high degree
of protection against carriage, consistent with the observed
data [2, 4]. Following this honeymoon period, the model pre-
dicted a strong resurgence in disease incidence if there was no
long-term immunization strategy. Of the long-term strategies
we investigated, a combination strategy of routine EPI vaccina-
tion after 5 years together with a catch-up campaign targeting
children aged 1–4 years who were born after the initial cam-
paigns was the most effective, although there was considerable
overlap in the distribution of results for different strategies.
Routine EPI alone appeared to be more effective than periodic
mass campaigns, unless EPI coverage was low (less than approx-
imately 60%). The model ﬁndings, in addition to comprehen-
sive information from clinical trials in children aged <1 year
were presented to the World Health Organization’s Strategic
Advisory Group of Experts (SAGE) on immunization in Octo-
ber 2014 [21].
These ﬁndings suggest, ﬁrst, that it is essential to implement a
long-term strategy for the continued use of MenAfriVac. It is
not sufﬁcient for the vaccine only to be used in a large one-
off campaign, as this may result in catastrophic resurgences in
disease 10–20 years after vaccine introduction. All of the long-
term strategies considered were effective in maintaining disease
control, although for all strategies incidence was predicted to
rise over the long term as population immunity from the initial
campaigns waned. The inclusion of MenAfriVac into the rou-
tine EPI as a single dose at 9 months of age has the obvious ad-
vantage of using and likely strengthening existing infrastructure.
The option to conduct periodic campaigns may, however, pro-
vide better disease control for those countries with very poor
routine EPI uptake. The combination strategy of introduction
into routine EPI with a one-off catch-up campaign targeting
those born since the initial campaign was the most effective
and also the most equitable option. Indeed, SAGE recommend-
ed that countries should adopt such a strategy within 5 years of
campaign completion [22].
Our work has several strengths and limitations. Our model
structure was based on extensive previous work that used a
range of deterministic models, to explore the importance of sea-
sonality and immunity following colonization [12]. As such, we
feel we have good understanding of the underlying system dy-
namics. We extended these models to incorporate age structure
and vaccination, and included a stochastic term so that the ex-
tent of seasonal forcing varied from year to year, to capture the
effect of external forces (including, eg, dust or humidity condi-
tions) [23].We parameterized the model using appropriate pub-
lished and unpublished data speciﬁc to African populations as
far as possible. Some model parameters were unknown, includ-
ing the transmission rate and duration of natural immunity.
Here, we used a variety of methods to estimate a sensible
range and feasible parameter combinations, ensuring that the
model produced realistic results by comparing the model
predictions to evidence on carriage prevalence by age, disease
incidence by age, total annual incidence, seasonality, and peri-
odicity. Further investigation of formal ﬁtting methods such as
Approximate Bayesian Computation is warranted [24], and
more information on a range of parameters would be desirable,
including age-speciﬁc contact patterns. Quantifying the dura-
tion of natural immunity following infection is particularly dif-
ﬁcult; estimation is hampered by codependence with other
parameters, and empirical measurement is problematic, not
least because of the lack of an absolute correlate of protection
[25]. We performed sensitivity analyses to investigate parameter
uncertainty and showed that our ﬁndings were robust.
Our conclusions are different from another model of
MenAfriVac, which found that mass campaigns were superior
to routine EPI. This is probably largely because the duration
of protection assumed by Tartof et al was much greater
(essentially lifelong) for children immunized in campaigns
than through EPI [13], whereas we assumed that protection
in 1- to 4-year-olds would be similar to those immunized at
the age of 9 months, based on recent data from the MVP’s
MenAfriVac trials. Tartof et al also used a different model
structure, a larger time step, noncontinuous aging, a smaller
number of simulations, and a higher frequency (weekly) and
amplitude (0–0.75) of stochastic forcing. We chose a more
parsimonious model structure that did not consider variable
levels of protection against colonization and disease, as there
was little evidence to inform such a structure and its param-
eterization. We explored the effect of other structural changes
in our model, including the implementation of stochasticity
as weekly variation in transmission rates, but this had mi-
nor effects on the model predictions and did not change
our conclusions on the relative merits of each immunization
strategy.
Following its introduction in 2010, MenAfriVac has been re-
markably successful in controlling MenA disease. This success
will not be maintained without a long-term immunization strat-
egy. The early adopting countries will need to consider immi-
nently how best to sustain population protection against MenA,
and ﬁndings from mathematical models such as this can lend
further support to decision makers at both the country level
and internationally.
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Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
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